Suppr超能文献

伊朗同种异体移植组织处理

Iranian homograft tissue processing.

作者信息

Rouchi Alireza Heidary, Tavakoli Seyed Amirhosein, Mahdavi-Mazdeh Mitra

机构信息

Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Glob Cardiol Sci Pract. 2016 Mar 31;2016(1):e201607. doi: 10.21542/gcsp.2016.7.

Abstract

Tissue transplantation is a life-enhancing therapeutic modality for damaged or non-functioning tissues. In most cases, there is no alternative other than human tissue as replacement, and taking into account the ever-increasing demand for tissue grafts, it makes sense to set up an establishment in charge of human tissue procurement to meet local needs. A quality assurance system, clearly defined standards, and regular audits complement the infrastructure which make this activity feasible. The process of tissue procurement consists of donor identification, consent, tissue recovery, donor screening and testing, tissue processing, preservation, packaging, labeling, terminal sterilization, storage and distribution. The transplantation of homograft heart valves remains controversial, due to the availability of prosthetic and bioprosthetic alternatives. The limited durability of homografts has not yet outweighed the advantages which this graft offers. Adherence to regulations and regularly revised guidelines improve long-term efficacy and minimizes complications or malfunction. Furthermore, the lower price of homograft heart valves and the removal of the need for a lifetime of anticoagulation therapy are noteworthy advantages of this replacement. In our practice, the proportion of homograft heart valves meeting release criteria and successfully implanted grafts were 83% and 95%, respectively.

摘要

组织移植是一种改善受损或功能失常组织的治疗方式。在大多数情况下,除了人体组织作为替代物外别无他选,考虑到对组织移植物的需求不断增加,设立一个负责人体组织获取的机构以满足当地需求是合理的。一个质量保证体系、明确界定的标准以及定期审核完善了使这项活动可行的基础设施。组织获取过程包括供体识别、同意、组织回收、供体筛查和检测、组织处理、保存、包装、标记、最终灭菌、储存和分发。同种异体心脏瓣膜移植仍存在争议,因为有假体和生物假体替代物可供选择。同种异体移植物有限的耐用性尚未超过这种移植物所提供的优势。遵守法规和定期修订的指南可提高长期疗效并将并发症或故障降至最低。此外,同种异体心脏瓣膜价格较低以及无需终身抗凝治疗是这种替代物值得注意的优势。在我们的实践中,符合放行标准的同种异体心脏瓣膜比例和成功植入的移植物比例分别为83%和95%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d8f/5642825/83b863e5b518/gcsp-2016-1-e201607-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验